Astellas seeks conditional approval for GA treatment in Japan
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
EyePoint stock jumps 10% on Duravyu study results
EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the ...
Daily1h
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
INVISIONMAG2h
Prevent Blindness Declares February as AMD and Low Vision Awareness Month
The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...
pharmaphorum3h
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Optician's warning to 'stop habit' or risk rising 'silent killer'
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...
Optician's warning to 'stop habit' or risk 'silent killer' that is on rise
Smoking damages the blood vessels in the eyes, which over time increases the risk for several complications, including ...
Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...
'Good' cholesterol may be linked to heightened glaucoma risk among over 55s
"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Business Wire20h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...